8-K: Kymera's KT-621 Shines in Atopic Dermatitis Phase 1b Trial

Kymera Therapeutics announced positive Phase 1b clinical trial results for its oral STAT6 degrader KT-621 in moderate to severe atopic dermatitis patients, showing strong efficacy and a favorable safety profile.

Summary

• KT-621 demonstrated deep and consistent STAT6 degradation, with median reductions of 98% in blood and 94% in skin lesions at Day 29 across both 100 mg and 200 mg doses.
• Robust reductions were observed in Type 2 inflammatory biomarkers, including TARC (median 74% reduction in patients with baseline TARC levels comparable to dupilumab AD studies), Eotaxin-3 (median 62-73% reduction), IL-31 (median 54-56% reduction), and IgE (median 5-14% reduction).
• Significant clinical activity was reported, with mean Eczema Area and Severity Index (EASI) score reductions of 63% across all patients at Day 29, showing rapid onset by Day 8.
• EASI-50 (50% improvement from baseline) responder rates were 76% across all patients, and EASI-75 (75% improvement from baseline) rates were 29%.
• Mean Peak Pruritus Numerical Rating Scale (NRS) reductions were 40% across all patients at Day 29, with measurable impact as early as Day 8.
• Total SCORing Atopic Dermatitis Index (SCORAD) scores decreased substantially, with a mean reduction of 48% across all patients at Day 29.
• Meaningful improvements in patient-reported quality of life were observed, as measured by the Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure (POEM).
• KT-621 showed activity in comorbid asthma patients (median FeNO reduction of 56%, 100% ACQ-5 responder rate) and allergic rhinitis patients (meaningful improvements in TNSS and RQLQ measures).
• The drug was well-tolerated with a favorable safety profile, reporting no serious adverse events (SAEs), no severe AEs, and no related treatment-emergent-adverse events (TEAEs) leading to discontinuation.

Sentiment

Score: 9

Explanation: The filing reports overwhelmingly positive Phase 1b clinical trial results for KT-621, demonstrating strong efficacy across multiple biomarkers and clinical endpoints, a favorable safety profile, and activity in comorbid conditions. The results are explicitly stated to have exceeded expectations and, in several instances, numerically surpassed published data for a leading competitor (dupilumab) at week 4. This strong performance for a first-in-class oral treatment significantly de-risks the program and expands its potential.

Positives

• Deep and consistent STAT6 degradation (98% in blood, 94% in skin) validates the mechanism of action and translates strongly from healthy volunteers to AD patients.
• Robust reductions in multiple Type 2 inflammatory biomarkers (TARC, Eotaxin-3, IL-31, IgE, FeNO) indicate broad anti-inflammatory effects.
• Eotaxin-3 reductions numerically exceeded what has been reported with dupilumab in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) patients even at 52 weeks.
• First known demonstration of IL-31 and FeNO reduction in AD patients with IL-4/13 pathway blockade, providing initial proof of concept for lung inflammation inhibition.
• Significant clinical improvements in EASI (63% mean reduction), EASI-50 (76%), EASI-75 (29%), Peak Pruritus NRS (40% mean reduction), and SCORAD (48% mean reduction).
• Rapid onset of action observed for EASI and pruritus by Day 8, the earliest timepoint reported.
• Improvements were generally comparable to or in some cases numerically exceeded published data for dupilumab at week 4 across various clinical endpoints.
• Favorable safety profile with no SAEs, severe AEs, related TEAEs leading to discontinuation, conjunctivitis, herpes infections, or arthralgias.
• Demonstrated activity in comorbid asthma (median FeNO reduction of 56%, 100% ACQ-5 responder rate) and allergic rhinitis, supporting broader potential across Type 2 diseases.
• KT-621 is a first-in-class, oral STAT6 degrader, offering potential convenience and accessibility over injectable biologics.

Negatives

• Cross-trial comparisons to dupilumab may not be reliable as no head-to-head trials have been conducted, and data may not be directly comparable due to differences in molecule composition, trial protocols, dosing regimens, and patient populations.
• Phase 1/1b clinical data for KT-621 is not predictive of, may be inconsistent with, or less favorable than data generated from future or ongoing clinical trials.

Risks

• Cross-trial comparisons to dupilumab may not be reliable as no head-to-head trials have been conducted, and Phase 1/1b clinical data for KT-621 may not be directly comparable due to differences in molecule composition, trial protocols, dosing regimens, and patient populations and characteristics.
• Results from the Phase 2b KT-621 trial may differ from the Phase 1/1b KT-621 data.
• Preclinical and clinical data, including the results from the Phase 1/1b trial of KT-621, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate.
• Uncertainties inherent in the initiation, timing, and design of future clinical trials.
• The availability and timing of data from ongoing and future clinical trials and the results of such trials.
• The ability to successfully demonstrate the safety and efficacy of drug candidates.
• The timing and outcome of planned interactions with and submissions to regulatory authorities.
• The availability of funding sufficient for operating expenses and capital expenditure requirements and other factors.

Future Outlook

The company plans to accelerate KT-621 development with the ongoing BROADEN2 Phase 2b trial in moderate to severe AD patients and the planned BREADTH Phase 2b trial in asthma, which is set to start in the first quarter of 2026. These studies are intended to enable dose selection for subsequent parallel Phase 3 registration studies across multiple Type 2 dermatology, gastroenterology, and respiratory indications. Data from the AD Phase 2b trial is expected to be reported by mid-2027.

Management Comments

• Nello Mainolfi, PhD, Founder, President and CEO: "The BroADen study results exceeded our highest expectations and provide a powerful additional validation of our industry-leading STAT6 degrader program."
• Nello Mainolfi, PhD, Founder, President and CEO: "KT-621 demonstrated its potential to deliver a first-in-class once-a-day oral treatment for Type 2 inflammatory diseases across every measure we evaluated... The results were in line with, or in some cases numerically exceeded, published data for dupilumab at week 4 and we believe further reinforce Kymera’s pioneering expertise in developing transformative oral small molecules with the potential for the activity and safety of injectable biologics."
• Jared Gollob, MD, Chief Medical Officer: "The most impressive outcome of our BroADen study is the consistency that KT-621 demonstrated in all measured endpoints: STAT6 degradation, reduction of blood Type 2 biomarkers, including the first known demonstration of impact of IL-4/13 pathway blockade on IL-31 and FeNO in AD patients, and reduction of core Type 2 inflammation and AD disease-relevant gene sets in skin lesions."
• Jared Gollob, MD, Chief Medical Officer: "KT-621 achieved these results at doses that were well-tolerated, exhibiting a safety profile consistent with what we observed in the Phase 1a healthy volunteer study."
• Eric Simpson, MD, MCR, Frances J. Storrs Medical Dermatology Professor and Director of CLEAR Eczema Center, Oregon Health & Science University: "There remains a clear need for new oral therapies that can address the underlying biology of the disease while potentially offering patients greater convenience. KT-621’s novel mechanism and encouraging early data showing impact on clinical endpoints and biomarkers of Type 2 inflammation highlight the potential for this program to expand the options for people living with AD as well as other Type 2 allergic diseases."

Industry Context

KT-621, as a first-in-class, oral STAT6 degrader, is positioned to be a significant disruptor in the treatment of Type 2 inflammatory diseases. Its oral administration offers a substantial convenience advantage over current injectable biologics, such as dupilumab, which are standard for moderate to severe atopic dermatitis and other Type 2 conditions. The strong efficacy and favorable safety profile demonstrated in this Phase 1b trial suggest KT-621 could address a critical unmet need for effective and convenient oral therapies, potentially expanding treatment options and capturing a notable share of the market for these widespread conditions.

Comparison to Industry Standards

• KT-621 achieved a median TARC reduction of 74% at Day 29 in patients with baseline TARC levels comparable to dupilumab AD studies (defined as ≥1,600 pg/mL), which is in line with published dupilumab results at week 4.
• Median Eotaxin-3 reductions of 62% (100 mg) and 73% (200 mg) at Day 29 numerically exceeded what has been reported with dupilumab in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) patients even at 52 weeks.
• Median IgE reductions of 5% (100 mg) and 14% (200 mg) at Day 29 were comparable to reported dupilumab data at week 4.
• Mean EASI score reductions (62-63%) and EASI-50 (67-83%) and EASI-75 (25-33%) responder rates were in line with or in some cases numerically exceeded published data for dupilumab at week 4.
• In AD patients with comorbid asthma (n=4), KT-621 achieved a median FeNO reduction of 56% at Day 29, which numerically exceeded published data for dupilumab at week 4 in asthma patients.
• Skin transcriptomics results, showing decreases in core Type 2 inflammation and AD disease-relevant gene sets, were comparable to dupilumab at week 4.

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical data, significant de-risking of a lead asset, and expanded market potential, likely leading to increased company valuation and investor confidence.
• Patients (Atopic Dermatitis, Asthma, Allergic Rhinitis): Potential for a new, convenient, and highly effective oral treatment option for moderate to severe Type 2 inflammatory diseases, offering improved quality of life and symptom relief.
• Employees: Positive impact from successful clinical development, potentially leading to increased job security, opportunities for growth, and a boost in company morale.
• Competitors: Increased competitive pressure, particularly for companies developing or marketing injectable biologics for Type 2 inflammatory diseases, as KT-621 offers an oral alternative with comparable or superior early efficacy.

Next Steps

• Continue the KT-621 BROADEN2 Phase 2b trial in moderate to severe AD patients, with patient dosing already commenced.
• Report data from the BROADEN2 Phase 2b trial by mid-2027.
• Start the BREADTH Phase 2b trial in asthma in the first quarter of 2026.
• Accelerate KT-621 development to enable dose selection for subsequent parallel Phase 3 registration studies across multiple Type 2 dermatology, gastroenterology, and respiratory indications.

Key Dates

Recommendation

The Phase 1b results for KT-621 are exceptionally strong, demonstrating deep target degradation, robust biomarker modulation, and significant clinical efficacy that is comparable to, and in some cases numerically superior to, a leading injectable biologic (dupilumab) at week 4. The favorable safety profile and the potential for an oral, first-in-class treatment for a broad range of Type 2 inflammatory diseases represent a significant market opportunity and competitive advantage. This data substantially de-risks the program and provides a clear path to advanced clinical development and potential market entry, making Kymera Therapeutics a highly attractive investment.

Keywords

Kymera Therapeutics, KT-621, STAT6 degrader, atopic dermatitis, AD, eczema, Phase 1b, clinical trial, Type 2 inflammation, dupilumab, asthma, allergic rhinitis, oral treatment, biopharmaceutical, targeted protein degradation, TPD